Oncology Blue Book Part 2 Flashcards

1
Q

what causes myelosuppression

A

can be a result of disease or chemotherapy due to siping out own body’s cells in bone marrow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

aetiology of myelosuppression

A

treatment related –> cytotoxic and biological agent, causes a transient fall of leukocytes and platelet count in conventional dose but worse in higher dose

bone marrow infiltration –> infiltration of malignant cells into the bone marrow and cause pancytopenia

para-neoplastic syndrome –> syndrome caused by the production of hormone/cytokines by tumour cells leading to an immune response by the body leading to depletion of leukocytes etc

other –> anaemia caused by a tumor and chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

when does myelosuppression usually come on

A

10-12 days post inital engagement of chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

which cancer more likely to cause bone marrow infiltration

A

lung breast prostate (those cancer in particular that invade bones)

haematological cancer –> leukomai, lymphoma etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

which type of myelosuppression does carboplatin cause

A

thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

which biological agents causes myelossuppression

A

interforon

interleukin-2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Ix for myelosuppression

A

full evaluation incl blood film, measurement of haematinics, bone marrow aspirate and trephine (bone marrow test)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

treatment for myelosuppression due to anaemia

A

gold standard = transfusion but the loss of risks

recombinant erythropoietin –> stimulate EPO and so stimulate RBC production from bone marrow level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what level of HB is considered to be impairing QOL

A

< 10 g/dl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

presentation of thrombocytopenia

A

petechial haemorrhage, spontaneous nose bleeds, corneal haemorrhage, haematuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what level of platlet is considered life-threatening

A

< 10x10(9)/L –> significant risk of spontaneous risk of bleeding eg intra-cerebral haemorrhage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

treatment of thrombocytopenia when platelet level of < 10x10 9

A

urgent platelet transfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what platelet support is given when HB level between 10-20x10 (9)

A

frequent transfusion of platelet but not urgent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

treatment of thrombocytopenia when platelet is > 20x10 (9)

A

usually nothing unless spontanoues bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what can repeat platelet transfusion cause

A

specifice antibbodies produced by the body itself targeting the transfused platelet

using of a singler donor or a donor with HLA matched platelet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what level of WBC is considered to be infection prone

A

< 1x10(9)/L

17
Q

management of a patient present with fever post chemo

A

medical emergency due to the possbility of neutropenic sepsis

board spectrum ABx - local Leeds guideline –> Tazosine

18
Q

what examination should be avoided in patients presentation consistent of neutropenic sepsis

A

PR or vaginal exam to avoid any breach to the mucosa leading to the infection risk

19
Q

management of persistent pyrexia despite correct Abx treatment

A

additional anti-fungal or anti-viral agents

20
Q

treatment of pneumocystis pneumonia

A

co-trimoxazole

21
Q

what are some of the prevention method of myelosuppression

A

prophylactic ABx –> only used in those pt with myelosuppression and other co-morbidity leading to inc infection risk eg COPD and risk of pneumonia

dose modifications –> red dose of chemo = dec severity of myelosuppression

colony stimulating factors –> current no evidence to prove the effectiveness of this treatment

22
Q

what are some of the novel discovery in recent biological therapy

A

1) further understanding of the biological process of tumour formation
2) pathway which tumour cells subverting the immune system of the body